Phase 2 × Recruiting × Squamous Cell Carcinoma of Head and Neck × Clear all Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
188 enrolled
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Phase 2 Recruiting
44 enrolled
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Phase 2 Recruiting
120 enrolled
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Phase 2 Recruiting
150 enrolled
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
92 enrolled
Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
Phase 2 Recruiting
30 enrolled
WOLF
Phase 2 Recruiting
87 enrolled
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Phase 2 Recruiting
100 enrolled
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
40 enrolled
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Phase 2 Recruiting
98 enrolled
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Phase 2 Recruiting
70 enrolled
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Phase 2 Recruiting
32 enrolled
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Phase 2 Recruiting
32 enrolled
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Phase 2 Recruiting
45 enrolled
eVOLVE-02
Phase 2 Recruiting
257 enrolled
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Phase 2 Recruiting
189 enrolled
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
120 enrolled
POST-BIO
Phase 2 Recruiting
45 enrolled
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Phase 2 Recruiting
38 enrolled
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Phase 2 Recruiting
30 enrolled
KIEO
Phase 2 Recruiting
30 enrolled
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Phase 2 Recruiting
27 enrolled
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
Phase 2 Recruiting
29 enrolled
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Phase 2 Recruiting
12 enrolled
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Phase 2 Recruiting
25 enrolled
RAD RAPTORS
Phase 2 Recruiting
42 enrolled
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
Phase 2 Recruiting
21 enrolled
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
Phase 2 Recruiting
108 enrolled
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Phase 2 Recruiting
40 enrolled
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
Phase 2 Recruiting
250 enrolled
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Phase 2 Recruiting
66 enrolled
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Phase 2 Recruiting
520 enrolled
REDUCE
Phase 2 Recruiting
86 enrolled
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 Recruiting
28 enrolled
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
Phase 2 Recruiting
80 enrolled
TRINITY
Phase 2 Recruiting
21 enrolled
LIFTING2
Phase 2 Recruiting
60 enrolled
Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
Phase 2 Recruiting
30 enrolled
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Phase 2 Recruiting
492 enrolled
HN001
Phase 2 Recruiting
90 enrolled
A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma
Phase 2 Recruiting
24 enrolled
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
Phase 2 Recruiting
150 enrolled
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
Phase 2 Recruiting
70 enrolled
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
60 enrolled
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
81 enrolled
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Phase 2 Recruiting
50 enrolled
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
Phase 2 Recruiting
225 enrolled
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
Phase 2 Recruiting
98 enrolled
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Phase 2 Recruiting
50 enrolled
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Phase 2 Recruiting
200 enrolled